Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer

被引:1
|
作者
Peters, Gabrielle W. [1 ]
Talcott, Wesley [1 ]
Peters, Nicholas V. [2 ]
Dhanasopan, Andrew [3 ]
Lacy, Jill [4 ]
Cecchini, Michael [4 ]
Kortmansky, Jeremy [4 ]
Stein, Stacey [4 ]
Lattanzi, Stephen [4 ]
Park, Henry S. [1 ]
Boffa, Daniel [3 ]
Johung, Kimberly L. [1 ]
Jethwa, Krishan R. [5 ]
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT USA
[2] Yale Univ, Dept Gen Surg, Sch Med, New Haven, CT USA
[3] Yale Univ, Dept Thorac Surg, Sch Med, New Haven, CT USA
[4] Yale Univ, Dept Med Oncol, Sch Med, New Haven, CT USA
[5] Mayo Clin, Radiat Oncol, Rochester, MN USA
关键词
Induction chemotherapy; esophageal cancer; gastroesophageal cancer; PHASE-II TRIAL; NEOADJUVANT CHEMORADIOTHERAPY; TREATMENT TIME; PLUS SURGERY; THERAPY; SURVIVAL; IMPACT;
D O I
10.21037/jgo-22-1005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: For patients with operable locally advanced esophageal carcinoma (LA-EC), we hypothesized that pre-operative induction chemotherapy followed by chemoradiotherapy (IC-CRT) would improve progression-free survival (PFS) and overall survival (OS) when compared to chemoradiotherapy (CRT). Methods: This was a single institution retrospective cohort study including patients with LA-EC who received preoperative-intent IC-CRT vs. CRT between 2013-2019. The Kaplan-Meier method was used to estimate OS and PFS. Cox proportional hazards regression was used to assess for variables associated with survival. The impact of treatment group on pathologic response was assessed by chi-square. Results: Ninty-five patients were included for analysis (IC-CRT n=59; CRT n=36) and the median followup was 37.7 months (IQR: 16.8-56.1). There was no difference in median PFS or OS for IC-CRT or CRT, 22 months (95% CI: 12-59) vs. 32 months (95% CI: 10-57) (P=0.64) and 39 months ( 95% CI: 23-not reached) vs. 56.5 months (95% CI: 38-not reached) (P=0.36), respectively. Amongst the subset of patients with adenocarcinoma histology, there was no difference in median PFS or OS, nor was there when analyses were further restricted to those who received >= 3 cycles of induction 5-fluorouracil and platinum, or for those who underwent esophagectomy. Pathologic complete response occurred in 45% vs. 29% (P=0.24) and N-stage regression occurred in 72% vs. 58% (P= 0.28) of patients in the IC- CRT and CRT cohorts, respectively. Distant metastasis occurred in 44% of patients in each treatment cohort. Conclusions: For patients with LA-EC, preoperative-intent IC-CRT was not associated with improved PFS or OS when compared with CRT.
引用
收藏
页码:1181 / +
页数:16
相关论文
共 50 条
  • [21] Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
    Byun, Sang Jun
    Kim, Jin Hee
    Kim, Ok Bae
    Song, Hong Suk
    RADIATION ONCOLOGY JOURNAL, 2011, 29 (01): : 20 - 27
  • [22] Induction chemotherapy followed by response evaluation and esophagectomy for advanced esophageal cancer
    van der Zijden, Charlene J.
    van der Sluis, Pieter C.
    Mostert, Bianca
    Nuyttens, Joost J. M. E.
    Spaander, Manon C. W.
    Toxopeus, Eelke L. A.
    Valkema, Roelf
    Beerepoot, Laurens V.
    van Halteren, Henk K.
    Lagarde, Sjoerd M.
    Wijnhoven, Bas P. L.
    EJSO, 2024, 50 (03):
  • [23] Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locally advanced hypopharyngeal cancer
    Su, Che-Wei
    Lee, Jehn-Chuan
    Chang, Yi-Fang
    Su, Nai-Wen
    Lee, Pei-Hsuan
    Dai, Kun-Yao
    Tai, Hung-Chi
    Leu, Yi-Shing
    Chen, Yu-Jen
    TUMORI JOURNAL, 2022, 108 (05): : 450 - 460
  • [24] Pre-versus postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
    Hsu, Po-Kuei
    Chen, Hui-Shan
    Liu, Chia-Chuan
    Huang, Chien-Sheng
    Hsieh, Chih-Cheng
    Hsu, Han-Shui
    Wu, Shiao-Chi
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2017, 154 (02) : 732 - +
  • [25] Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer
    Masashi Hashimoto
    Yasuhiro Shirakawa
    Naoaki Maeda
    Shunsuke Tanabe
    Kazuhiro Noma
    Kazufumi Sakurama
    Kuniaki Katsui
    Masahiko Nishizaki
    Toshiyoshi Fujiwara
    Esophagus, 2020, 17 : 127 - 134
  • [26] Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer
    Steffen, Thomas
    Dietrich, Daniel
    Schnider, Annelies
    Kettelhack, Christoph
    Huber, Olivier
    Marti, Walter R.
    Furrer, Markus
    Gloor, Beat
    Schiesser, Marc
    Thierstein, Sandra
    Brauchli, Peter
    Ruhstaller, Thomas
    ANNALS OF SURGERY, 2019, 269 (01) : 83 - 87
  • [27] Induction Chemotherapy Before Chemoradiotherapy in Locally Advanced Head and Neck Cancer: The Future?
    Paccagnella, Adriano
    Mastromauro, Cataldo
    D'Amanzo, Paola
    Ghi, Maria Grazia
    ONCOLOGIST, 2010, 15 : 8 - 12
  • [28] Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis
    Liang, Zhanpeng
    Chen, Ting
    Li, Wenxia
    Lai, Huiqin
    Li, Luzhen
    Wu, Jiaming
    Zhang, Huatang
    Fang, Cantu
    MEDICINE, 2024, 103 (03) : E36785
  • [29] Effects of pre-operative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy: protocol for a multicenter randomized controlled trial (point trial, pre-operative immunonutrition therapy)
    Cao, Yuqin
    Han, Dingpei
    Yang, Su
    Shi, Yongmei
    Zhao, Shengguang
    Jin, Qianwen
    Li, Jian
    Li, Chengqiang
    Zhang, Yajie
    Shen, Weiyu
    He, Jinxian
    Wang, Mingsong
    Ji, Guangyu
    Li, Zhigang
    He, Yi
    Chen, Qixun
    Wei, Weitian
    Chen, Chun
    Gong, Xian
    Wang, Jinyi
    Tan, Lijie
    Wang, Hao
    Li, Hecheng
    BMC CANCER, 2022, 22 (01)
  • [30] Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
    Xia, Xiaojie
    Wu, Mengxing
    Gao, Qing
    Sun, Xinchen
    Ge, Xiaolin
    CURRENT ONCOLOGY, 2022, 29 (09) : 6342 - 6349